Table 1.
Baseline characteristics.
| Total (N = 57) | Non-Survivors (N = 13) | Survivors (N = 42) | |
|---|---|---|---|
| Characteristics | |||
| Age, years | 72 [60–81] | 81 [76–86] | 65 [56–78] |
| Female sex | 13 (23%) | 2 (15%) | 10 (24%) |
| Initial symptoms | |||
| Fever | 39 (68%) | 9 (69%) | 29 (69%) |
| Cough | 34 (60%) | 10 (77%) | 23 (55%) |
| Dyspnea | 25 (44%) | 4 (31%) | 21 (50%) |
| Fatigue | 21 (37%) | 3 (23%) | 18 (43%) |
| Gastrointestinal Symptoms | 17 (30%) | 1 (8%) | 16 (38%) |
| Diarrhea | 13 (23%) | 0 (0%) | 13 (31%) |
| Emesis | 3 (5%) | 1 (8%) | 2 (5%) |
| Nausea | 9 (16%) | 1 (8%) | 8 (19%) |
| Tiredness | 16 (28%) | 1 (8%) | 15 (36%) |
| Myalgia | 12 (21%) | 1 (8%) | 11 (26%) |
| Loss of Taste | 10 (18%) | 1 (8%) | 9 (21%) |
| Loss of Smell | 9 (16%) | 1 (8%) | 8 (19%) |
| Headache | 7 (12%) | 0 (0%) | 7 (17%) |
| Sore throat | 4 (7%) | 0 (0%) | 4 (7%) |
| Angina pectoris | 4 (7%) | 0 (0%) | 4 (10%) |
| Pharyngalgia | 3 (5%) | 1 (8%) | 2 (5%) |
| Rhinorrhoea | 2 (4%) | 0 (0%) | 2 (5%) |
| Symptom onset to Hospitalization, days | 4 [0–7] | 0 [0–2] | 6 [1–7] |
| Inpatient treatment | |||
| Patients with antibiotic therapy1 | 22 (39%) | 9 (69%) | 11 (26%) |
| Duration of antibiotic therapy, days | 5 [4–6] | 4 [4, 5] | 5 [4–7] |
| COVID-19 specific treatment | – | – | – |
| Periods, days | |||
| Fever days | 7 [2–11] | 8 [4–11] | 8 [2–11] |
| Hospitalization | 12 [7–20] | 9 [6–15] | 13 [8–20] |
| Oxygen supplementation | 8 [5–13] | 7 [4–10] | 9 [5–13] |
| Outcome | |||
| Survivor | 42 (74%) | – | – |
| Non-Survivor | 13 (23%) | – | – |
| Ongoing hospitalization | 2 (4%) | – | – |
| Discharge location | |||
| Home | 39 (68%) | – | 39 (93%) |
| Rehabilitation | 0 (0%) | – | – |
| Hospice | 0 (0%) | – | – |
| Nursing facility | 3 (5%) | – | 3 (7%) |
| Discharge with oxygen therapy | 3 (5%) | – | 3 (5%) |
Data in N (%) or Median [IQR].
IQR, Interquartile range.
aAntibiotic classes most commonly used: aminopenicillines, cephalosporines.